Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Epidermal Cell Suspension vs. Silver Sulfadiazine in Second Degree Burns
NCT03162367Phase 2Completed
- Sponsor
- SCARM Institute
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous epidermal cell suspension in burn injury (2 arms), sponsored by SCARM Institute. Primary endpoint: Percentage of re-epithelization at 20 days. Started Apr 2019; status: completed.
02
Drugs
autologous epidermal cell suspension
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT03162367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162367.